Getting Mounjaro without diabetes is possible but rarely the best route. Mounjaro is approved by the FDA only for type 2 diabetes, so using it for weight loss is off-label, and insurers and Lilly’s savings card generally won’t pay for that use.[1][7] The same drug, tirzepatide, is approved for weight management and obstructive sleep apnea as Zepbound, which is usually easier to get covered and cheaper to buy without insurance ($299 to $449 a month vs $499 for Mounjaro).[2][9][10]
Prices and program terms checked October 2026. They change often; confirm with the manufacturer or your plan.
For how tirzepatide works, see our tirzepatide profile.
Mounjaro vs Zepbound: same drug, different approvals
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide[1] | Tirzepatide[2] |
| Approved for | Type 2 diabetes (ages 10 and up); lowering heart attack and stroke risk in adults with type 2 diabetes[1] | Weight management in adults; moderate to severe obstructive sleep apnea in adults with obesity[2] |
| First approved | 2022[1] | Weight management, November 2023; sleep apnea, December 2024[3][4] |
| Strengths | 2.5 to 15 mg weekly[1] | 2.5 to 15 mg weekly[2] |
| Forms | Single-dose pen[9] | Single-dose pen, single-dose vial, four-dose KwikPen[10] |
| Self-pay through LillyDirect | From $499 a month[9] | $299 to $449 a month (vial or KwikPen)[10] |
Both labels start at 2.5 mg weekly and increase by 2.5 mg at least every 4 weeks, up to a maximum of 15 mg.[1][2] A clinician sets the dose. See our tirzepatide dosage chart and Zepbound vs Mounjaro.
Can a doctor prescribe Mounjaro off-label?
Yes. The FDA explains that once a drug is approved, health care providers may prescribe it for an unapproved use when they judge it medically appropriate for a patient.[5] So a clinician can legally write a Mounjaro prescription for someone without diabetes.
In practice, though, there is little reason to. Since November 2023, tirzepatide has had its own approval for chronic weight management as Zepbound.[3] Prescribing Zepbound for weight management is an on-label use, which matters for insurance, savings programs and the instructions you receive.
Why the on-label product matters beyond cost
The two labels share the same safety warnings, including the boxed warning about thyroid C-cell tumors seen in rodents, but they give different guidance for different goals.[1][2]
- Maintenance doses: Zepbound’s label lists 5 mg, 10 mg or 15 mg as maintenance doses for weight reduction, and 10 mg or 15 mg for sleep apnea.[2] Mounjaro’s label is written around blood sugar control.[1]
- Low blood sugar warnings: Mounjaro’s label discusses low blood sugar mainly when it is combined with insulin or a sulfonylurea, other diabetes medicines.[1]
- Pharmacy and plan records: an on-label prescription matches the diagnosis on file, which makes prior authorization, refills and savings programs simpler.
None of this changes the drug itself. It changes how smoothly you can get it and pay for it.
The evidence in people without diabetes
Zepbound’s weight-management approval rests on trials in adults without diabetes. In SURMOUNT-1, 2,539 adults with obesity, or overweight plus a related condition, took tirzepatide or placebo for 72 weeks. Average weight loss was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, versus 3.1% on placebo.[6] The sleep apnea approval came from two trials in 469 adults with obesity, also without type 2 diabetes.[4]
Insurance: why Mounjaro without diabetes is usually denied
Insurers cover drugs for specific diagnoses. For Mounjaro, plans commonly require documented type 2 diabetes. For example:
- BCBS of Vermont keeps covering GLP-1 drugs such as Mounjaro with prior approval for type 2 diabetes, but from January 1, 2026 members using a GLP-1 for anything other than diabetes or Wegovy’s heart indication pay the full cost.[8]
- Lilly’s Mounjaro Savings Card requires a prescription for an approved use that matches the drug’s label, so off-label weight-loss use does not qualify.[7]
If your plan does cover weight-loss drugs, it will usually route you to Zepbound with prior authorization rather than Mounjaro. See does insurance cover Zepbound?
Your realistic options without diabetes
- Zepbound through a plan that covers weight-loss drugs. Prior authorization usually requires a BMI of 30 or more, or 27 or more with a weight-related condition.[2] With coverage, the Zepbound savings card can lower the cost to as little as $25. See the Zepbound savings card guide.
- Zepbound for obstructive sleep apnea. If you have moderate to severe OSA and obesity, some plans that exclude weight-loss drugs cover Zepbound for OSA.[4] See Zepbound for sleep apnea.
- Medicare GLP-1 Bridge. Eligible Part D members prescribed Zepbound for weight management can get the KwikPen for $50 a month from July 1, 2026 through December 31, 2027.[11] See does Medicare cover Zepbound?
- Self-pay Zepbound through LillyDirect. Vials or the KwikPen cost $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg when refilled within 45 days.[10] See Zepbound cost without insurance.
- Self-pay Mounjaro. LillyDirect sells Mounjaro from $499 a month with a prescription,[9] but for the same drug, Zepbound’s self-pay price is lower at every dose.
What if you have prediabetes?
Prediabetes is not type 2 diabetes, so it does not by itself meet Mounjaro’s approved use.[1] It can count as a weight-related condition for Zepbound coverage on some plans, and it is one of the qualifying conditions (with a BMI of 27 or more) for the Medicare GLP-1 Bridge.[11]
Questions to ask your prescriber
- Is Zepbound or Mounjaro the right product for my diagnosis?
- Do I meet my plan’s prior authorization criteria for Zepbound?
- Would a sleep study be appropriate if I have symptoms of sleep apnea?
- Which form (pen, vial or KwikPen) fits my coverage or budget?
For a full price comparison, see tirzepatide cost. Compounded tirzepatide is not approved by the FDA and is not a substitute for either brand; our compounded tirzepatide guide explains why.
